I-Ocrevus (ocrelizumab) - Izifundo Zokusebenza

I-Ocrevus (ocrelizumab) isidakamizwa sebhayoloji esisetshenziselwa ukwelapha i-multiple sclerosis (MS) kanye ne-rheumatoid arthritis (RA). Umuthi wagunyazwa yi-FDA ngo-2017 ukuze welaphe i-MS futhi ngo-2021 ukwelapha i-RA.

Isenzo se-Ocrevus sisekelwe ekuvimbeni amaprotheni e-CD20, akhona ebusweni bamanye amangqamuzana amasosha omzimba, kuhlanganise namaseli adlala indima ebalulekile ekuthuthukiseni i-MS ne-RA. Ukuvimbela amaprotheni e-CD20 kunganciphisa ukusebenza kwamasosha omzimba futhi kunciphise ukuvuvukala okuholela ekulimaleni kwezicubu.

Izifundo ngokusebenza kwe-Ocrevus ekwelapheni i-MS ne-RA zenziwe iminyaka eminingana. Olunye lwezifundo zokuqala, olwanyatheliswa kuyi-Lancet ngo-2017, lwabizwa ngokuthi "Ukusebenza kahle nokuphepha kwe-Ocrevus ku-primary progressive multiple sclerosis." Ucwaningo lwenziwa ezigulini ezingaphezu kuka-700 ezathola i-Ocrevus noma i-placebo amasonto angama-96. Imiphumela yabonisa ukuthi u-Ocrevus wehlise kakhulu ukuqhubeka kwe-MS uma kuqhathaniswa ne-placebo.

Olunye ucwaningo olwanyatheliswa kuyi-New England Journal of Medicine ngo-2017 lwaphenya ukusebenza kwe-Ocrevus ekubuyiseleni kabusha-remitting multiple sclerosis (RRMS). Ucwaningo lwenziwa ezigulini ezingaphezu kuka-1300 ezathola i-Ocrevus noma omunye umuthi wokwelapha i-RRMS. Imiphumela ikhombise ukuthi i-Ocrevus inciphise kakhulu isibalo sokubuyela emuva ezigulini uma kuqhathaniswa nomunye umuthi.

Izifundo ngokusebenza kwe-Ocrevus ku-RA nazo zenziwe. Omunye wabo, owashicilelwa ku-Lancet ngo-2019, wahlola ukusebenza kwe-Ocrevus ku-seropositive RA, okungenye yezinkinga ezinzima kakhulu.